Platinum-based drug triplatin failed in phase II clinical trials, but a new insight could lay the groundwork for a comeback — ScienceDaily
A study by Virginia Commonwealth University Massey Cancer Center researchers published in today’s print edition of Molecular Cancer Therapeutics shows that triplatin is effective against triple negative breast cancer, which…
